Grünenthal Stories
Grünenthal announced that the company has enrolled the first patient in its global clinical Phase III programme for resiniferatoxin (RTX).
RTX is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist, with a well-validated mechanism of action. The discovery of TRPV1 was awarded the Nobel Prize of Physiology or Medicine in 2021. If approved, resiniferatoxin may provide patients with long-lasting pain relief with a favourable safety profile.
Grünenthal starts global clinical Phase III programme for resiniferatoxin (RTX)
2021 Disclosures

How do you run a pharmaceutical business responsibly?
We believe it means creating a net positive impact for patients, employees, partners and wider society, while working towards reducing its impact on the environment.
Our first Grünenthal Responsibility Report follows GRI standards and provides transparent information about our progress.

Interested in partnering with Grünenthal PRO?
Meet us from November 1-3, 2022 at the CPhI Worldwide in Frankfurt, Germany - Booth 120F12

Grünenthal 2022 - A story of transformation
- An industry-leading pipeline fueled by cutting-edge science
- Record financial results and a company value that has tripled over the last years
- Reducing our footprint on the planet, recognized by a strong ESG rating

Careers
Working at Grünenthal means experiencing the impact you can have on the results we achieve and the lives of the patients we serve.
Join forces.
Make an impact.
Innovate for a world free of pain.